<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01820611</url>
  </required_header>
  <id_info>
    <org_study_id>GBMET.CR.US19</org_study_id>
    <nct_id>NCT01820611</nct_id>
  </id_info>
  <brief_title>Arcos Revision Stem: Evaluation of Clinical Performance</brief_title>
  <official_title>Arcos Revision Stem: Evaluation of Clinical Performance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the clinical performance of the Arcos&#xD;
      Revision Stem system, determine the stability of the implants, and evaluate any relationship&#xD;
      between Paprosky bone defect level and the success of the Arcos Stem.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Endpoint: survivorship and revision rate up to 5 years post-operatively Secondary&#xD;
      Endpoints: Stability and Fixation of Arcos Hip by radiographic assessment, Relationship&#xD;
      between bone defect level and survivorship, Oxford Hip Score and Harris Hip Score&#xD;
      post-operative, Adverse events, complications.&#xD;
&#xD;
      Case Report Forms: Demographic Data, Paprosky Acetabular/Femoral Defects, Operative Data,&#xD;
      Oxford Hip Score, Harris Hip Score, Collection of X-rays, Radiographic Evaluation form,&#xD;
      Adverse Events, Revisions, Lost to Follow-up, and Protocol Deviations&#xD;
&#xD;
      200 patients: 100 with BoneMaster HA, 100 without BoneMaster HA. Up to 10 sites globally will&#xD;
      be used to fulfill enrollment in this study.&#xD;
&#xD;
      All cases enrolled will be those implanted with either the Cone, Broached, or Calcar Proximal&#xD;
      Body and one of the five distal options (Slotted, Bullet-tip, Interlocking, STS, or ETO).&#xD;
&#xD;
      To be included in the study, a patient must have received a revision total hip arthroplasty&#xD;
      with the Arcos system. The Arcos system is to be used in accordance to the indications for&#xD;
      use and contraindications detailed in the approved labeling of the device.&#xD;
&#xD;
      Study time perspective:&#xD;
&#xD;
      Collection of retrospective data in supplement to the data collected in the course of the&#xD;
      prospective study to compensate total enrolment goal. This is applicable for 3 sites:&#xD;
      Finland, United Kingdom (NHS Sheffield), Spain.&#xD;
&#xD;
      All patients enrolled in the study will be followed up as tot he same time points for the&#xD;
      duration of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">June 14, 2021</completion_date>
  <primary_completion_date type="Actual">June 14, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survivorship &amp; Revision Rate</measure>
    <time_frame>5 year follow-up</time_frame>
    <description>Survivorship &amp; Revision Rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stability and Fixation of Arcos Hip by radiographic assessment</measure>
    <time_frame>5 year follow-up</time_frame>
    <description>Stability and Fixation of Arcos Hip by radiographic assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between bone defect level and survivorship</measure>
    <time_frame>5 year follow-up</time_frame>
    <description>Before surgery, the Paprsoky Classification will be used to determine the femoral and acetabular defect level in order to create a baseline measurement that will then be used for making comparisons and analyzing outcomes in terms of survivorship.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxford Hip Score</measure>
    <time_frame>5 year follow-up</time_frame>
    <description>Oxford Hip Score - patient reported outcome measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Harris Hip Score</measure>
    <time_frame>5 year follow-up</time_frame>
    <description>Harris Hip Score - patient reported outcome measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>5 year follow-up</time_frame>
    <description>Adverse Events</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">200</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Avascular Necrosis</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Deformity</condition>
  <condition>Fracture</condition>
  <condition>Complications; Arthroplasty</condition>
  <arm_group>
    <arm_group_label>With Bonemaster HA</arm_group_label>
    <description>100 patients using Arcos Revision Stem System with BoneMaster Hydroxyapatite</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without BoneMaster HA</arm_group_label>
    <description>100 patients using Arcos Revision Stem System without BoneMaster Hydroxyapatite</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Arcos Revision Stem System</intervention_name>
    <description>Revision Hip System</description>
    <arm_group_label>With Bonemaster HA</arm_group_label>
    <arm_group_label>Without BoneMaster HA</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include patients who had a revision to a total hip replacement&#xD;
        using the Arcos Revision Stem Hip System.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Noninflammatory degenerative joint disease including osteoarthritis and avascular&#xD;
             necrosis&#xD;
&#xD;
          -  Rheumatoid arthritis&#xD;
&#xD;
          -  Correction of functional deformity&#xD;
&#xD;
          -  Treatment of non-union, femoral neck fracture, and trochanteric fractures of the&#xD;
             proximal femur with head involvement, unmanageable using other techniques.&#xD;
&#xD;
          -  Revision of previously failed total hip arthroplasty.&#xD;
&#xD;
        The Arcosâ„¢ Modular Femoral Revision System hip components are single-use implants, intended&#xD;
        for uncemented use only.&#xD;
&#xD;
        Only subjects who have received or have already been scheduled to receive hip surgery with&#xD;
        the Arcos Revision Stem System will be included in this outcomes study.&#xD;
&#xD;
        Additional Inclusion Criteria:&#xD;
&#xD;
          -  No age limit, however, the patient must have reached full skeletal maturity.&#xD;
&#xD;
          -  Willing to return for follow up evaluation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Absolute contraindications include: active infection, sepsis, and osteomyelitis.&#xD;
&#xD;
        Relative contraindications include:&#xD;
&#xD;
          -  Uncooperative patient or patient with neurologic disorders who are incapable of&#xD;
             following directions&#xD;
&#xD;
          -  Osteoporosis&#xD;
&#xD;
          -  Metabolic disorders which may impair bone formation&#xD;
&#xD;
          -  Osteomalacia&#xD;
&#xD;
          -  Distant foci of infections which may spread to the implant site&#xD;
&#xD;
          -  Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram&#xD;
&#xD;
          -  Vascular insufficiency, muscular atrophy, or neuromuscular disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Russell Schenck</last_name>
    <role>Study Director</role>
    <affiliation>Zimmer Biomet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Mutua</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uddevalla Hospital</name>
      <address>
        <city>Uddevalla</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hinchingbrooke Hosptial</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS - Sheffield Teaching Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 19, 2013</study_first_submitted>
  <study_first_submitted_qc>March 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2013</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

